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Background: Schizophrenia patients and their parents have an increased risk of immune disorders compared to
population controls and their parents. This may be explained by genetic overlap in the pathogenesis of both
types of disorders. The purpose of this study was to investigate the genetic overlap between schizophrenia
and three immune disorders and to compare with the overlap between schizophrenia and two disorders not
primarily characterized by immune dysregulation: bipolar disorder and type 2 diabetes.
Methods:We performed a polygenic risk score analysis using results from the schizophrenia Psychiatric GWAS
consortium (PGC) (8922 cases and 9528 controls) and ﬁve Wellcome Trust Case Control Consortium (WTCCC)
case samples as target cases: bipolar disorder (n = 1998), type 1 diabetes (n = 2000), Crohn's diseases (n =
2005), rheumatoid arthritis (n = 1999), and type 2 diabetes (n = 1999). The WTCCC British Birth Cohort
and National Blood Service samples (n = 3004) were used as target controls. Additionally, we tested whether
schizophrenia polygenic risk scores signiﬁcantly differed between patients with immune disorder, bipolar
disorder, and type 2 diabetes respectively.
Results: Polygenic risk scores for schizophrenia signiﬁcantly predicted disease status in all three immune disorder
samples (Nagelkerke-R2 1.1%–1.3%; p b 0.05). The polygenic risk of schizophrenia in patients with immune
disorders was signiﬁcantly lower than in patients with bipolar disorder (Nagelkerke-R2 6.0%; p b 0.05), but
higher than in type 2 diabetes patients (Nagelkerke-R2 0.5%; p b 0.05).
Conclusions: Our results suggest that genetic factors are shared between schizophrenia and immune disorders.
This contributes to an accumulating body of evidence that immune processes may play a role in the etiology of
schizophrenia.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Schizophrenia is to a large extent inﬂuenced by genetic factors
(Sullivan et al., 2003). The genetic architecture is complex: between
23% and 50% of the variance is explained by thousands of independent
common genetic variants (Lee et al., 2012; Ripke et al., 2013), suggest-
ing a polygenic model in which a large number of genetic variants
contribute to disease risk (Purcell et al., 2009; Lee et al., 2012). Epidemi-
ological studies have shown increased incidence of immune disorders in
patients with schizophrenia and their relatives. A large epidemiological
study performed in Denmark, including 7704 patients with schizophre-
nia and 192,590matched controls without a psychiatric record, showed
that schizophrenia patients have a 45% higher lifetime incidence of one
or more immune disorders which were present prior to the onset of
schizophrenia compared to matched controls (Eaton et al., 2006). This
increased risk is not merely a consequence of the psychiatric disorder
since the diagnosis of immune disorder was made before the onset of
schizophrenia. Furthermore, the incidence rate ratio (IRR) was alsox 75867, 1070AW Amsterdam,
701.higher in parents of schizophrenia patients than among parents of
comparison subjects. The risk for 12 out of 29 reported immune disor-
ders in parents of schizophrenia patients was signiﬁcantly increased,
whereas no signiﬁcant decrease in risk was reported for any of the
disorders (Eaton et al., 2006).
The increased incidence of immune disorders in schizophrenia
patients and their parents is generally consistent with other epidemio-
logical ﬁndings (Leucht et al., 2007; Eaton et al., 2010; Chen et al.,
2012). A notable exception is the risk of rheumatoid arthritis, which
has been found to be increased in parents of schizophrenia patients
compared to parents of controls (Gilvarry et al., 1996; Eaton et al.,
2006), whereas other epidemiological studies comparing patients
with controls have reported schizophrenia to be a protective factor
for rheumatoid arthritis (Leucht et al., 2007; Chen et al., 2012).
This discrepancy suggests that although environmental and disease-
related factors may protect schizophrenia patients from rheumatoid
arthritis, genetic or other family-related factors may increase the risk
of rheumatoid arthritis.
One of the hypotheses for the increased incidence of immune
disorders in schizophrenia patients and their relatives is that common
molecular pathways are involved in the pathogenesis of both types of
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tribute to a higher incidence of both schizophrenia and immune
diseases. Obvious candidates for such shared genetic risk factors include
the variants in the human leukocyte antigen (HLA) region which con-
tribute to the risk of schizophrenia (Purcell et al., 2009; Stefansson
et al., 2009). In addition, a recent study showed that a relatively large
segment at chromosome 5 is enriched for single nucleotide polymor-
phisms (SNPs) which are signiﬁcantly associated with schizophrenia
(Gladwin et al., 2012). This region contains genes previously found to
be related with schizophrenia (e.g., ACSL6, NEUROG1) and many
immune-related genes, such as interleukin (IL)-4, IL-5, IL-13, and
transforming growth factor (TGF) β-1. Interestingly, linkage studies
had already implicated chromosome 5q31 in both schizophrenia and
Crohn's disease (Schwab et al., 2000; Rioux et al., 2001).
Thus far, the genetic overlap between schizophrenia and auto-
immune disorders has been investigated by targeted approaches
which focus on the role of speciﬁc candidate genes or regions which
may contribute to the risk of both types of disorders. However, like
schizophrenia, immune disorders have a complex genetic architecture
(Goris and Liston, 2012; Parkes et al., 2013). Therefore, a more
systematic approach would be to study the genetic overlap between
schizophrenia and immune disorders based on genome-wide associa-
tion data using polygenic risk score analysis (Purcell et al., 2009).
Polygenic risk scores are a measure of disease liability and can be used
to investigate the genetic overlap between disorders at a genome-
wide level.
The aim of this study is to investigate the genome-wide genetic
overlap between schizophrenia and three disorders primarily charac-
terized by immune dysregulation: type 1 diabetes, rheumatoid arthritis,
and Crohn's disease. We compare the genetic overlap between schizo-
phrenia and immune disorder patients with the overlap between
schizophrenia and bipolar and type 2 diabetes patients, a psychiatric
disease and a somatic disease which is not primarily characterized by
immune dysfunction.
2. Methods
2.1. Data
We used results from the schizophrenia Psychiatric GWAS
Consortium (PGC) data, a large collection of 17 case–control GWAS
samples of European descent (9394 cases and 12,462 controls in total)
(Ripke et al., 2011), to compute polygenic risk scores in ﬁve case–
control samples from the Wellcome Trust Case Control Consortium
(WTCCC) (Burton et al., 2007). The case samples included type 1 diabe-
tes (T1D) (n = 2000), rheumatoid arthritis (RA) (n = 1999), Crohn's
disease (CD) (n = 2005), bipolar disorder (BD) (n = 1998), and type
2 diabetes (BD) (n = 1999) (Burton et al., 2007). These case samples
were chosen to compare the three immune disorders (i.e., rheumatoid
arthritis, Crohn's disease, and type 1 diabetes)with a psychiatric disease
(bipolar disorder) and a somatic disorder which is not primarily charac-
terized by immune dysfunction (type 2 diabetes). For all disorders the
same WTCCC control subjects from the National Blood Service (NBS)
(n = 1500) and 1958 Birth Cohort (1958BC) (n = 1504) were used
(Burton et al., 2007).
2.2. Quality control
We ﬁrst removed subjects and SNPs that the WTCCC recommended
to exclude (Burton et al., 2007). See Fig. S1 in the Supplemental infor-
mation for a detailed ﬂow chart of the subsequent pre-imputation Filter
1 to 5. Before merging theWTCCC case and control samples, we applied
the following ﬁltering steps to the seven WTCCC subsamples using
PLINK (Purcell et al., 2007): minor allele frequency (b0.01), genotype
missingness (N0.05), individual missingness (N0.02), genotype
missingness once again (N0.02) (Filter 1), Hardy–Weinberg equilibriumin controls (p b 0.001) (Filter 2), and minor allele frequency difference
with a HapMap reference panel (N0.1) (Filter 3). The reference panel
consisted of HapMap III founders from the CEPH Utah residents with
Northern and Western European ancestry sample (CEU) and Tuscans
in Italy (TSI) sample (n = 200) (Altshuler et al., 2010).
After combining the NBS and 1958BC control samples, we removed
SNPs signiﬁcantly (p b 10−8) associated with control sample member-
ship (Filter 4). Subsequently, we combined case and control samples
for each disorder, applied Filter 1 again to the resulting case–control
samples, and removed any SNPs which were extremely signiﬁcantly
(p b 10−50) associated with disease status (Filter 5).
2.3. Principal component analysis
To correct for population stratiﬁcation, we then calculated ten
principal components for each WTCCC case–control sample. Each
case–control sample was pruned to ensure relative independence be-
tween SNPs (PLINK command –indep-pairwise 50 5 0.2) for principal
component analysis. The remaining SNPs were used to calculate ten
principal componentswith EIGENSTRAT (Price et al., 2006).We similar-
ly computed ten principal components for all cases combined to allow
for correction of population stratiﬁcation in a direct comparison of
diseases (see section).
2.4. Imputation
After principal component analysis, all WTCCC subsamples were
imputed with Beagle (Browning and Browning, 2007) using the
HapMap Phase III CEU + TSI founders (version 2, build 36) as a refer-
ence panel (Altshuler et al., 2010). SNPs with a quality threshold of
r2 b 0.6 were excluded. The 113,664 independent SNPs remaining
after the schizophrenia PGC clumping analysis were considered for
upstream analysis (Ripke et al., 2011). Further post-imputation QC
consisted of removing SNPs with MAF b 0.01. Additionally, subjects
identiﬁed as outliers (s.d. N 6) during principal component analysis
were removed from the case–control samples. One of the members of
a pair of relatives (pi-hat N 0.2 in PLINK) was removed as well.
Table S1 in the Supplemental information shows the number of subjects
and SNPs retained per case–control sample after these preprocessing
steps.
2.5. Meta-analysis of PGC schizophrenia effect sizes
Wemeta-analyzed the effect sizes of the PGC schizophrenia samples
(Ripke et al., 2011) using a ﬁxed effects model in METAL (Willer et al.,
2010), excluding the Cardiff UK sample to prevent overlap with the
WTCCC controls (resulting in 8922 cases and 9528 controls).
2.6. Polygenic risk score analysis
Based on the meta-analyzed log(odds ratios) we computed additive
schizophrenia polygenic risk scores for individuals in all ﬁve
preprocessed WTCCC case–control samples using PLINK (Purcell et al.,
2007). Based on different p-value thresholds for association with
schizophrenia (p b 0.1 to p b 1 with steps of 0.1), we created different
subsets of SNPs to compute the polygenic risk scores. These threshold-
dependent polygenic risk scores were then standardized and used as
a predictor in logistic regression to predict disease status in each
respective case–control sample. Standardization limits the range of the
coefﬁcients, but does not affect the Nagelkerke-R2 and p-values. To
account for differences in population structure, we ﬁrst included only
10 PCA components as covariates in the logistic regression and then
added the polygenic risk score in a second model. We used the
difference in Nagelkerke's pseudo-R2 between the two nested models
to represent the effect of polygenic risk score above and beyond the
effect of population stratiﬁcation. The Nagelkerke R2 is analogous, but
Fig. 1. Predictive power (Nagelkerke R2) of schizophrenia polygenic risk score for ﬁve
diseases: bipolar disorder (BD), type-1 diabetes (T1D), Crohn's disease (CD), rheumatoid
arthritis (RA), and type-2 diabetes (T2D). Different bars represent p-value thresholds for
the SNPs used in the analysis. SNPs located at chromosome six are excluded. Horizontal
black lines identify an empirical 5% signiﬁcance threshold based on 1000 random permu-
tations of case–control labels in the validation sample. p-Value of differences between
disorders is based on a pairwise comparison of polygenic risk scores in respective cases
corrected for 10 PCA components and pthreshold b 1.
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HLA region, we performed the polygenic risk score analysis with and
without SNPs located on chromosome six to check whether genetic
overlap was limited to SNPs on chromosome six or was distributed
across the genome.
Similar to Purcell et al. (2009), for each analysis we reported the
logistic regression coefﬁcient of the risk prediction score with standard
error and the difference in Nagelkerke-R2 between the two nested
models. To assess signiﬁcance, the Nagelkerke's pseudo-R2 was
compared with a one-sided 95% conﬁdence interval of an empirical
null distribution. This null distribution was created by repeating the
same analysis a 1000 times while randomly permuting disease status
in the respective WTCCC case–control sample.
2.7. Comparison of disorders
We assessed whether bipolar disorder, immune disorders, and
type 2 diabetes differ signiﬁcantly in terms of genetic overlap with
schizophrenia. For this analysis, we combined immune cases in one
group and performed an overall comparison of the polygenic risk
score in the three resulting case groups with an ANCOVA, correcting
for population stratiﬁcation (ten PCA components which were calculat-
ed in the combined case samples). To explore which groups were
signiﬁcantly different, we compared the risk score of immune cases
with that of bipolar disorder cases and type 2 diabetes cases respective-
ly, similarly correcting for population stratiﬁcation.
3. Results
All diseases were positively associated with schizophrenia. In other
words, a higher genetic risk for schizophrenia was associated with a
higher genetic risk for each of the ﬁve disorders (see positive coefﬁ-
cients in Table 1). Fig. 1 shows the predictive power of the schizophre-
nia polygenic risk score, excluding chromosome six, which harbors the
immune related HLA region. Different thresholds for p-values in the
schizophrenia data were used; e.g., pthreshold = 0.1 indicates that only
those SNPs with a p-value below 0.1 in the schizophrenia data were
included in the polygenic score analysis. Includingmore SNPs generally
resulted in improved prediction. This implies that many small effect
SNPs associated with schizophrenia are involved in all ﬁve disorders.
The extent to which the genetic liability for schizophrenia predicted
disease status in another disorder varied. As expected, bipolar disorder
was best predicted by schizophrenia polygenic risk score (maximum
Nagelkerke-R2 6.0%; pemp b 0.01; empirical p value based on 1000
permutations). The risk of three immune disorders type 1 diabetes,
Crohn's disease, and rheumatoid arthritis was also signiﬁcantly associ-
ated with the schizophrenia risk score (maximum Nagelkerke-R2
ranged between 1.1%–1.3%; pemp b 0.01). It is worth noting that exclud-
ing or including chromosome six had a relatively minor impact on the
results (maximum difference in Nagelkerke-R2 = 0.2%). This indicates
that the HLA region is not themajor driving force behind the association
between schizophrenia risk score and disease status in immune disor-
ders. Finally, type 2 diabetes was least predicted by the genetic liability
for schizophrenia (maximum Nagelkerke-R2 0.5%; pemp b 0.01).Table 1
Results of polygenic risk score analysis based on all SNPs (pthreshold b 1).a
Excluding chromosome six
Trait β s.e. p Pseudo-R2
BD 0.51 0.035 3.7 × 10−47 6.02%
T1D 0.21 0.032 2.8 × 10−11 1.25%
CD 0.20 0.033 1.4 × 10−9 1.11%
RA 0.21 0.032 1.8 × 10−11 1.31%
T2D 0.13 0.032 5.7 × 10−5 0.45%
a Logistic regression coefﬁcient (β), standard error of β (s.e.), and p-value of β (p) of polygen
(BD), type 1 diabetes (T1D), Crohn's disease (CD), rheumatoid arthritis (RA), and type 2 diabeTo assess whether the differences between bipolar disorder,
immune disorders, and type 2 diabetes were signiﬁcant, we combined
type 1 diabetes, Crohn's disease, and rheumatoid arthritis in one
group of immune cases. The mean schizophrenia polygenic risk scores
in the three case groups (immune vs. bipolar disorder vs. type 2 diabe-
tes)were signiﬁcantly different (F(2, 7957)= 83.0; p b 0.05). Polygenic
risk scores differed signiﬁcantly between bipolar cases and immune
cases (p b 0.05; based on SNPs with pthreshold b 1) as well as between
immune cases and type 2 diabetes cases (p b 0.05; based on SNPs
with pthreshold b 1) (see Table S2 in the Supplemental information for
pairwise comparisons for all ﬁve disorders).
4. Discussion
To increase our understanding of the association between
schizophrenia and immune disorders in epidemiological studies, we
performed a polygenic risk score analysis in which a genetic risk score
based on schizophrenia data predicted the risk of three immune
disorders: type 1 diabetes, Crohn's disease, and rheumatoid arthritis.
We report that the genetic liability for schizophrenia signiﬁcantly
predicts disease status of all three immune disorders. This implies that
immune disorder patients show an increased genetic risk of schizophre-
nia compared to population controls.
The genetic overlap of schizophrenia with immune disorders is 1%
(Nagelkerke-R2), which is lower than the 6% overlap of schizophrenia
with bipolar disorder. The relatively large genetic overlap between
schizophrenia and bipolar disorder is consistent with earlier studies
based on a variety ofmethods that have reported a genetic link between
schizophrenia and bipolar disorder (Purcell et al., 2009; Huang et al.,
2010; Lee et al., 2013; Smoller et al., 2013). A similar analysis in 2009
on a smaller subset of the same data only found a genetic overlap
between schizophrenia and bipolar disorder (Purcell et al., 2009). In
that study no signiﬁcant genetic overlap was found between schizo-
phrenia and respectively Crohn's disease, rheumatoid arthritis, type 1,
and type 2 diabetes. The main difference between the present studyIncluding chromosome six
β s.e. p Pseudo-R2
0.52 0.035 1.1 × 10−48 6.24%
0.21 0.032 1.5 × 10−11 1.28%
0.20 0.033 8.0 × 10−10 1.14%
0.22 0.032 5.9 × 10−12 1.37%
0.13 0.032 2.7 × 10−5 0.49%
ic risk score with corresponding Nagelkerke pseudo-R2 for ﬁve disorders: bipolar disorder
tes (T2D).
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SNP effect sizes (8922 cases and 9528 controls vs 3322 cases and 3587
controls). In polygenic risk score analysis larger discovery sample sizes
improve the SNP effect size estimates, increasing power to detect
genetic overlap. For example, larger discovery sample sizes increased
the explained variance in schizophrenia test samples from 3% to 6%
(Purcell et al., 2009; Ripke et al., 2013). Hence, the signiﬁcant associa-
tions in the present study can be explained by the larger sample size
of the schizophrenia PGC data. This illustrates the value of replicating
a previous polygenic risk score analysis on a larger dataset.
Interestingly, the overlap between schizophrenia and immune
disorders was larger than the overlap of 0.5% between schizophrenia
and type 2 diabetes, which is not primarily characterized by immune
dysregulation. This also points towards the involvement of genetic
factors related to immune processes in schizophrenia, although we
cannot rule out the reverse; that brain processes causing schizophrenia
are involved in immune disorders. The small, but signiﬁcant, genetic
overlap between schizophrenia and type 2 diabetes may seem surpris-
ing at ﬁrst. However, there is recent evidence that schizophrenia and
type 2 diabetes are indeed genetically related. For example, relatives
from patients with a non-affective psychotic disorder have an increased
risk for diabetes (van Welie et al., 2013). In that study it was unknown
whether relatives were diagnosed with type 1 vs. type 2 diabetes, but
provided the larger prevalence of type 2 diabetes in adults, themajority
of the diabetes cases can be assumed to have type 2 diabetes. Also,
common immune-related pathways between schizophrenia and type
2 diabetes have been reported in a pathway analysis (Liu et al., 2013).
Finally, immuno-therapy can normalize insulin resistance in type 2
diabetes patients, suggesting an important role of the immune system
in type 2 diabetes as well (Winer et al., 2009). Summarizing, our results
support the hypothesized genetic overlap between schizophrenia and
immune processes, but future studies should explore the mechanisms
which explain the small genetic overlap between schizophrenia and
type 2 diabetes.
Our analysis excluded chromosome six with the HLA region
(Walters et al., 2013), showing that this region only partly contributes
to the genetic overlap between schizophrenia and immune disorders
(a decrease in Nagelkerke R2 b 0.22% after removal of chromosome
six). It is not surprising that the genetic overlap is not restricted to the
HLA region, since both schizophrenia and immune disorders have a
complex genetic architecture (Lees et al., 2011; Lee et al., 2012; Stahl
et al., 2012). In genome-wide association studies of immune disorders,
signiﬁcantly associated loci are not only found in the HLA region, but
are also located on many different chromosomes (Franke et al., 2010;
Stahl et al., 2010; Bradﬁeld et al., 2011). Our study suggests that it
is the genome-wide accumulation of shared loci with small effects
which drives the genetic overlap between schizophrenia and immune
disorders.
While our results suggest that a genetic liability for schizophrenia
increases the risk of rheumatoid arthritis, schizophrenia has been
repeatedly reported as a potent protective factor for rheumatoid
arthritis (e.g. Chen et al., 2012; see Leucht et al., 2007 for a recent
overview). This is not necessarily inconsistent, since medication or
other life style changes in schizophrenia patients may decrease the
risk of rheumatoid arthritis (Laan et al., 2009; Kato et al., 2011), while
genetic and shared environmental factors could still increase the risk
of arthritis. This is illustrated by Eaton and colleagues who showed
that incidence of rheumatoid arthritis in parents of schizophrenia
patients is larger than in parents of matched population controls
(Eaton et al., 2006).
In conclusion, our results contribute to an accumulating and
converging body of evidence that immunological factors play a role in
the etiology of schizophrenia (Eaton et al., 2006, 2010; Müller and
Schwarz, 2010; Chen et al., 2012; Sainz et al., 2012; Gardiner et al.,
2013; Horváth and Mirnics, 2014). Despite the increased interest in
the role of immune dysregulation in schizophrenia, many questionsremain. For example, our results do not rule out the possibility that
the genetic overlap between schizophrenia and immune disorders
mostly involves brain processes instead of immune processes. To clarify
the role of immune dysregulation in schizophrenia, it is necessary to
identifywhichbiological pathways are implicated in both schizophrenia
and immune disorders. A less ambitious but nonetheless important goal
is to determinewhether immunological components can also be identi-
ﬁed in other neuropsychiatric disorders. These unanswered questions
combined with the reported ﬁndings of the last few years make the
role of immune dysregulation in neuropsychiatric disorders a promising
and exciting area of research for the foreseeable future.
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